MYMD Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:43):

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease...

Stats
Šios dienos apimtis	20 278.00
Vidutinė apimtis	231 718
Rinkos kapitalizacija	6.92M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.0380 (1.18%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-24	Rivard Paul	Buy	150 000	Common stock
2023-08-17	Rivard Paul	Buy	25 000	Common stock
2023-06-07	Chapman Christopher C Jr	Buy	300 000	Employee Stock Option (Right to Buy)
2023-06-07	Kaplin Adam	Buy	150 000	Employee Stock Option (Right to Buy)
2023-06-07	Uzonwanne Jude	Buy	150 000	Employee Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 84 transactions
Buy: 8 636 568 \| Sell: 532 775

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: -0.15 (neutral)

Signal:(52.074) Neutral

MyMD Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

MyMD Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.20
( neutral )

-0.10
( neutral )

-0.48
( neutral )

-0.28
( neutral )

0.71
( moderate )

0.36
( neutral )

MyMD Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.59

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.59

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-11.68

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.850

Financial Reports:

No articles found.

MyMD Pharmaceuticals,

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.